1	
2	
3	Methods used to Account for Concurrent Analgesic Use in Randomized
4	Controlled Trials of Interventional Pain Treatments: A Meta-Epidemiologic Study
5	
6	
7	Balaji V Sridhar, MD, PhD, MPH ^a ; Andrew Humbert, PhD ^b ; Adam Babitts, DPT, PT ^b :
8	Carina Staab, DC, Med: ^c Clinton J. Daniels, DC, MS: ^{b,d} Malka Dhillon, BS; ^b Patrick
9	Heagerty, PhD ^e ; Joshua Goldenberg, ND ^f ; Mark Jensen, PhD; ^b Pradeep Suri, MD,
10	MSc ^{b,d,g}
11	
12	
13	^a Department of Occupational and Environmental Medicine, University of Washington
14	^b Department of Rehabilitation Medicine, University of Washington
15	^c Department of Child, Family, and Population Health Nursing, University of Washington
16	^d Rehabilitation Care Services, VA Puget Sound Health Care System
17	^e Department of Biostatistics, University of Washington
18	^f Helfgott Research Institute, National University of Natural Medicine
19	g Seattle Epidemiologic Research and Information Center, , VA Puget Sound Health Care
20	System

Corresponding Author: Pradeep Suri, MD, MSc. Mailing Address: Rehabilitation Care Services, VA Puget Sound Health Care System, S-RCS-117, 1660 S. Columbian Way, Seattle, WA, 98108; email: pradeep.suri@va.gov; phone 206-764-2673; fax 206-716-5977

21 <u>Running Title:</u> Concurrent analgesic use in pain trials

22 ABSTRACT

23	
24	Objective: The modest effect sizes of most pain treatments make it essential that
25	randomized controlled trials (RCTs) use methods that clearly define treatment effects of
26	interest and consider the role of concurrent treatments. This study aims to determine
27	how frequently concurrent analgesic use is reported in interventional pain RCTs and
28	how accounting for analgesic use can affect pain intensity outcomes.
29	Design: Meta-epidemiologic study.
30	Methods: We conducted a study of concurrent analgesic use among RCTs from a
31	recent systematic review of non-surgical interventional pain treatments (n= 37). We
32	calculated the prevalence of different methods used to report concurrent analgesic use.
33	We performed meta-analyses to compare treatment effects on pain intensity with vs.
34	without accounting for concurrent analgesic use via a novel quantitative composite
35	outcome, the "QPAC _{1.5} ."
36	Results: About half of interventional pain RCTs reported concurrent analgesic use, but
37	only one RCT directly accounted for concurrent analgesic use in their pain intensity
38	outcome. Analyses accounting for concurrent analgesic use using the $QPAC_{1.5}$
39	substantially increased the estimated treatment effect of interventions on pain intensity
40	by an average of -0.45 numeric rating scale points (95% CI -0.76 to -0.14; p<0.001),
41	as compared to analyses that did not adjust for analgesic use.
42	Conclusion: Concurrent analgesic use is sometimes reported in interventional pain

43 RCTs, but rarely accounted for when examining treatment effects on pain intensity.

- 44 Accounting for concurrent analgesic use changes the treatment effect of interest to
- ⁴⁵ remove differential analgesic rates and has the potential to significantly affect estimates
- 46 of effect sizes on pain treatments.

47

48 Keywords: analgesics, randomized controlled trial, bias, epidemiology

49

50

51

52 **INTRODUCTION**

Pain affects 100 million adults in the United States (US) and costs up to \$635 billion annually.^{1,2} Many interventional pain treatments have been developed to mitigate the negative impacts of pain. Randomized controlled trials (RCTs) provide the strongest level of evidence to support pain treatment effectiveness.^{3,4} However, the modest effect sizes of most current pain treatments make it essential that RCTs use the most rigorous analytic methods to reduce the likelihood that meaningful treatment effects are obscured by other factors.

The use of analgesics following randomization may be an important factor to 60 61 account for in interventional pain RCTs. Differential post-randomization analgesic use 62 between intervention and control groups in an RCT may reflect participants' efforts to self-manage pain intensity after receiving the randomized treatment, and such efforts 63 64 may decrease the magnitude of treatment effects on pain intensity in an RCT if not accounted for. ^{5,6} Our observation is that concurrent analgesic use is not well-reported 65 in many RCTs evaluating pain treatments and, even when reported, is not explicitly 66 considered when defining or estimating treatment effects on pain intensity. Consistent 67 with this, a systematic review of analgesic treatment RCTs for back pain and 68 neuropathic pain found that about half of trials allowed study-specified "rescue" 69 analgesic use and/or participants to continue to use analgesics other than the 70 randomized treatment.⁷ 71

A recent study by Suri et al. found that ignoring concurrent analgesic use in the analysis of pain RCTs may lead to substantial underestimation of treatment effects on pain intensity and may affect power.⁵ Simple methods of accounting for concurrent

75 analgesic use, such as analyzing analgesic use as a binary outcome or adjusting for it as a covariate, decreased power.⁵ Suri et al. proposed a new measure to account for 76 concurrent analgesic use: the Quantitative Pain and Analgesic Composite outcome 77 $(QPAC_{1.5})$. The QPAC_{1.5} is a composite measure that combines pain intensity and 78 concurrent analgesic use into a single 0 to 10 numeric rating scale (NRS) of pain 79 80 intensity. Prior work has suggested that concurrent analgesic use has an average impact on perceived pain intensity of 1.5 NRS points ⁶. Accordingly, the QPAC_{1.5} 81 attributes a 1.5-NRS-point weight to concurrent analgesic use when approximating a 82 83 research participant's counterfactual pain NRS rating that would have been reported in the absence of analgesic use, by adding 1.5 NRS points to a participant's conventional 84 pain intensity NRS rating if the participant is taking analgesics at the time of pain 85 intensity reporting. While the QPAC_{1.5} applies a 1.5-NRS-point weight to concurrent 86 analgesic use, the approach is flexible, and could instead apply a different weight if 87 appropriate for a given clinical population. The QPAC_{1.5} has the same range and 88 interpretation as the conventional pain intensity NRS, facilitating easy comparisons 89 between the two measures.⁵ Statistical simulations and analyses of trial data have 90 91 found that the QPAC_{1.5} may increase power in pain RCTs relative to analyses that look only at the total effects of treatment on pain intensity without removing impacts on pain 92 intensity that occur due to differential analoesic use.⁶ 93

To our knowledge, no prior studies have evaluated how often interventional pain RCTs report on concurrent analgesic use or examined whether the analysis methods used accounted for analgesic use when analyzing pain intensity outcomes. Similarly, no prior meta-analyses have compared treatment effects on pain intensity with and without

the use of methods to account for post-randomization concurrent analgesic use. 98 Therefore, we conducted a meta-epidemiologic study of concurrent analgesic use 99 reporting among RCTs included in a 2021 comprehensive systematic review of 100 emerging non-surgical interventional procedural treatments for pain.⁸ The primary study 101 aims were to examine (1) the prevalence of reporting concurrent analgesic use among 102 included RCTs, and (2) the methods used to account for concurrent analgesic use. A 103 secondary aim of the study was to investigate the impact of accounting for post-104 randomization concurrent analgesic use on estimated treatment effects on pain 105 intensity, using the QPAC_{1.5}. 106

107

108 METHODS

109 Data Source

110 Before any study-related activities began, the study protocol and analysis plan were registered on the Open Science Framework (https://osf.io/syug3/).⁹ We conducted a 111 112 meta-epidemiologic study of interventional pain treatment parallel-group RCTs identified 113 from a 2021 systematic review by Chou et al., to determine the prevalence of reporting 114 concurrent analgesic use and how analgesic use was accounted for in analyses of pain 115 intensity. This high-quality systematic review followed the methods suggested in the 116 Agency for Healthcare Research and Quality Methods Guide for Effectiveness and 117 Comparative Effectiveness Reviews, which was developed for the Evidence-based Practice Centers.⁸ The review methods were determined *a priori* using a protocol 118 developed through a process that included public input and was published on the 119

Agency for Healthcare Research and Quality (AHRQ) website

(https://effectivehealthcare.ahrg.gov/products/interventional-treatments-pain/protocol) 121 and on the PROSPERO systematic reviews registry (CRD42021226947). The AHRQ 122 review examined interventional procedures for acute and chronic pain that are either not 123 currently covered by the United States (US) Centers for Medicare & Medicaid Services 124 (CMS), or procedures that are covered but for which there is uncertainty or controversy 125 regarding their use, including: vertebral augmentation; cooled or pulsed radiofrequency 126 ablation (RFA); intradiscal and facet-joint platelet-rich plasma injections; other 127 intradiscal procedures; sphenopalatine blocks; occipital nerve stimulation; piriformis 128 injections; and peripheral nerve stimulation. The review included 37 trials published 129 between 2002 and 2020.⁸ 130

131

132 Data Extraction

Data elements of all trials were extracted from the published articles and cross-133 referenced with what was reported in the AHRQ systematic review. Extracted variables 134 included baseline characteristics of the control and intervention groups; whether 135 baseline concurrent analgesic use was reported in the intervention and control groups: 136 and if baseline concurrent analgesic use was reported, how it was measured and 137 reported. We also extracted whether concurrent analgesic use was reported post-138 randomization in control and intervention arms, and if it was reported, how it was 139 measured and reported. Finally, we extracted the primary pain intensity outcome at the 140 primary trial endpoint.¹⁰ If cross-over was allowed, the post-randomization time point 141

prior to cross-over was analyzed to preserve the benefits of randomization. All major 142 data elements were extracted by two or more reviewers (BS, AB, CS, CD, MD). Areas of 143 uncertainty were reviewed by the senior author (PS) and resolved by discussion. 144 145 Reported concurrent analgesic use and methods used to account for concurrent 146 analgesic use 147 Baseline concurrent analgesic use variables: If concurrent analgesic use was reported. 148 149 the manner of analgesic reporting was classified as reporting of average dose of medication, prevalence of opioid use, prevalence of non-opioid use, prevalence of 150 individual medication or medication category use, prevalence of any analgesic use, or 151

152 "other".

153 Post-randomization concurrent analgesic use variables at the primary trial endpoint. If concurrent analgesic use was reported, the manner of analgesic reporting was 154 classified using the same options as used for classifying the baseline analgesic use 155 reporting. If the primary trial endpoint was not explicitly noted in a trial, we decided a 156 *priori* to define the primary endpoint (for the purposes of this meta-epidemiologic study) 157 158 as the time point when the largest treatment effect was expected based on clinical knowledge, factoring in the expected onset of effect and duration of effect for both the 159 treatment and control groups. For example, for vertebroplasty and kyphoplasty, after 160 161 which pain relief is thought to be rapid, we reasoned that the maximal treatment effect would be at 1-month post-randomization. On the other hand, for RFA we reasoned that 162 163 the maximal treatment effect would be at 3 months post RFA (as relief after

radiofrequency is not expected to be immediate, and post-RFA periods of increased
 pain ["neuritis"] may occur).¹¹

Methods to account for concurrent analgesic use in the analysis of the primary pain 166 intensity endpoint: We classified the methods used to account for concurrent analgesic 167 168 use in the analysis of the primary pain outcome, including whether analgesic use was adjusted for as a covariate, analyzed as a binary outcome, incorporated into a 169 composite outcome, used for imputation of pain intensity, or "other". We planned a priori 170 to expand this list of categories as needed, depending on the frequency of the methods 171 to account for concurrent analgesic use encountered among included RCTs from the 172 173 AHRQ systematic review.

174

175 Data Analysis and Synthesis:

176 To address the descriptive primary aims of the study, we: (1) calculated the 177 prevalence of any concurrent analgesic use reported at baseline and post-178 randomization, (2) calculated the frequency of different methods of reporting analgesic 179 use, and (3) determined how frequently authors accounted for concurrent analgesic use 180 in the analysis of pain intensity outcomes. Although the primary aims were descriptive in nature, we anticipated based on the literature ⁷ that most of the trials would not report 181 concurrent analgesic use, that a high proportion of trials would ignore analgesic use 182 post-randomization when analyzing pain intensity outcomes, and that the most common 183 184 analytic method related to concurrent analgesic use in pain RCTs would be to analyze analgesic use as a separate binary outcome. Of note, this last method does not account 185

for concurrent analgesic use in the analysis of pain intensity outcomes *per se* but
 analyzes analgesic use as a secondary outcome, ignoring that analgesic use may be
 impacting the primary as-randomized comparison of treatment groups with regards to
 pain intensity.

190 We also conducted a meta-analysis of treatment effects on pain intensity measured using the conventional 0 to 10 Numeric Rating Scale of pain intensity (NRS) vs. 191 treatment effects measured using the recently-developed QPAC_{1.5} composite outcome. 192 This meta-analysis was conducted among the subset of trials that reported conventional 193 NRS outcomes and concurrent analgesic use (both of which are needed to calculate the 194 195 $QPAC_{1,5}$) for each of the intervention and control groups, at the primary trial endpoint. 196 As the use of analgesics may be associated with pain intensity, when calculating the standard deviation of the QPAC_{1.5} we assumed a correlation between analgesic use 197 and pain NRS of 0.08 based on a prior report;⁶ sensitivity analyses were conducted 198 using other assumptions for this correlation. The details of how the QPAC₁₅ was 199 200 calculated is provided in the Supplementary Materials.

Based on the theory underlying the QPAC_{1.5}, ⁵ this measure would be expected to 201 increase the estimated treatment effect in a given RCT if a direct treatment effect exists 202 when comparing the intervention and control groups and when analgesic use is 203 differential across groups. In contrast, if no direct treatment effect exists when 204 205 comparing the intervention and control treatments and when there is no treatment impact on analgesic use, then the QPAC_{1.5} would not be expected to change estimated 206 treatment comparisons.⁵ With this reasoning in mind, we pre-specified a subset of RCTs 207 208 from the AHRQ systematic review for further study in a meta-analysis comparing

209 different methods of accounting for post-randomization concurrent analgesic use on estimated treatment effects on pain intensity. In this subset of RCTs, we expected 210 clinically-relevant treatment effects a priori given the intervention and control treatments 211 212 involved. Accordingly, we hypothesized that, in this subset of RCTs, analyses of the QPAC_{1.5} would produce larger treatment effects than analyses of the conventional NRS. 213 As we have described elsewhere,⁵ the QPAC_{1.5} estimates a *controlled direct* treatment 214 effect, whereas the conventional NRS estimates a total treatment effect, so each of 215 216 these two measures targets a slightly different estimand. The subset of RCTs from the AHRQ review included those comparing (1) vertebral augmentation vs. usual care 217 control, and (2) cooled RFA vs. control.⁹ We also pre-specified (3) a group of "positive 218 control" interventional trials from outside the AHRQ review to include in the meta-219 220 analysis, in order to encompass another interventional pain treatment for which clinically-relevant treatment effects would generally be expected. For this positive 221 control group, we selected trials of transforaminal epidural steroid injections (TF ESI) vs. 222 223 control for lumbosacral radicular pain, as such trials have generally shown consistent statistically significant treatment effects on pain intensity in past RCTs.¹² Pain intensity 224 data for RCTs of TF ESI were extracted from a Cochrane systematic review, ¹² and 225 analgesic data were extracted from the original articles. 226

Any RCT in these 3 groups of trials which reported a pain intensity outcome at the time of the primary endpoint, and also reported concurrent analgesic use, contributed to the meta-analyses. We conducted random-effects meta-analyses. The first metaanalysis estimated the total treatment effect on pain intensity using the conventional pain intensity NRS. The second meta-analysis estimated the treatment effect on the

232 post-randomization proportion of concurrent analgesic use. These two meta-analyses examine standard outcomes that are typically reported in pain RCTs. The third meta-233 analysis estimated the approximate controlled direct treatment effect on pain intensity 234 using the QPAC_{1.5}.⁵ The QPAC_{1.5} assumes that the average impact of analgesic use is 235 a 1.5-NRS-point change in pain intensity, but otherwise estimates a well-defined 236 contrast in mean values of a weighted composite outcome so is more generally a valid 237 comparison.⁵ Last, the fourth meta-analysis directly assessed the impact of the QPAC₁₅ 238 239 by comparing the difference between analyses of treatment effects on pain intensity using paired analyses of the conventional pain NRS as compared to the QPAC_{1.5}. 240 Accordingly, the primary statistical inference for the secondary aim of this study was 241 based on the fourth meta-analysis; we note that the p-value produced by this meta-242 243 analysis is equivalent to that produced by the second meta-analysis (which examined the proportion of concurrent analgesic use across the included RCTs). We considered a 244 p-value <0.05 as the threshold for statistical significance. We examined the differences 245 in heterogeneity (I^2) of the meta-analyses with the conventional NRS vs. the QPAC_{1.5}. 246 Details of the meta-analyses can be found in the Supplemental Materials. 247

248

249 **RESULTS**

250

The characteristics of the 37 trials included in the current review are listed in Table 1. We found that 17 of 37 (46%) of trials reported concurrent analgesic use at baseline and that the most common method used was to report the prevalence of any opioid use (11 of 37 [30%] of all trials) (Table 2).

255 We also found that 20 of 37 (54%) of the studied trials reported concurrent analgesic use post-randomization and that the most common method used was to report the 256 prevalence of any analgesic use (11 of 37 (30%) of all trials) (Table 3). Four of 37 (11%) 257 258 of trials used analgesic scoring methods that were specific to their trial and not otherwise widely used in the field. For example, one trial created an arbitrary grading for 259 each type and/or dose of analgesic and summed the gradings across analgesics 260 used.¹³ The most common method of incorporating analgesic use in analyses was to 261 262 report analgesic use as a binary outcome. Fourteen of 37 (38%) of trials analyzed whether the pain intervention affected the frequency of analgesic use. Only one trial 263 accounted for concurrent analgesic use directly in their analysis of treatment effects on 264 pain intensity, by using a binary composite "responder" outcome. This responder 265 266 outcome was defined as a 30% pre-to-post reduction in pain intensity without an increase in pain medication.¹⁴ None of the included trials accounted for analgesic use 267 using the approach of treating the pain NRS as if it was missing when there is 268 concurrent analgesic use, a strategy that is sometimes used.¹⁰ 269

Only 5 trials from the AHRQ systematic review met our pre-specified inclusion 270 271 criteria (intervention-control comparisons for which clinically relevant treatment effects 272 were expected *a priori*) and had the requisite data needed to calculate the QPAC_{1.5} in 273 treatment and control groups (pain intensity outcome reporting and concurrent 274 analgesic use prevalence at the primary pain intensity endpoint), and therefore were included in the meta-analyses.^{15–19} Four meta-analyses were conducted in this 275 276 subgroup of 5 trials. Among the trials of transforaminal lumbar epidural steroid injections 277 from the Cochrane review that we considered for inclusion in the meta-analysis (the

"positive control" group),¹² none reported concurrent analgesic use at the primary
endpoint when pain intensity outcomes were reported. Therefore, the QPAC_{1.5} could not
be calculated for these studies and they were not included in the meta-analyses.

In the first meta-analysis, we examined treatment effects on the conventional pain 281 intensity NRS at the primary trial endpoint in the 5 trials that met our inclusion criteria. 282 This revealed a significant (beneficial) average treatment effect on pain intensity 283 comparing the interventional treatments to controls of -2.31 NRS points (95% CI -3.50 284 to -1.11, Supplemental Figure 1), reflecting less pain in those who received 285 interventional pain treatments. In the second meta-analysis, we estimated the average 286 treatment effect on the post-randomization proportion of concurrent analgesic use. We 287 found a statistically significant 30% lower proportion of analgesic use in patients who 288 received the interventional treatments (p<0.001), as compared to the control treatments 289 (Supplemental Figure 2). 290

In the third meta-analysis, we estimated treatment effects on pain intensity 291 measured using the QPAC_{1.5}. We found a large-magnitude treatment effect for 292 interventional pain treatments as compared to control treatments (Supplemental Figure 293 3), with an estimated difference of -2.77 points on the $QPAC_{1.5}$ (95% CI -4.17 to -1.37). 294 This treatment effect point estimate (-2.77 points) was slightly larger than the treatment 295 effect on the pain intensity NRS (-2.31 points) found in the first meta-analysis. One trial 296 of the 5 included in the meta-analysis, which had not show a statistically significant 297 improvement with the interventional treatment when analyzing the conventional pain 298 299 intensity NRS (Supplemental Figure 1), did show a statistically significant improvement with the interventional treatment when analyzing the QPAC_{1.5}.¹⁶ Finally, in the fourth 300

301	meta-analysis, on which we based our primary statistical inference, we estimated the
302	difference between treatment effects using the conventional pain NRS as reported and
303	treatment effects using the $QPAC_{1.5}$. We found a significantly larger overall treatment
304	effect with the $QPAC_{1.5}$ as compared to the standard analysis of the conventional NRS
305	while ignoring concurrent analgesic use, with a reduction in pain intensity of -0.45 NRS
306	points [95% CI -0.76 to -0.14]; p<0.001 (Figure 1). This indicates a nearly 0.5 NRS-
307	point larger treatment effect on pain intensity when accounting for concurrent analgesic
308	use via the $QPAC_{1.5}$. Heterogeneity with all four analyses was high (85-90%).
309	Sensitivity analyses assuming different correlations between concurrent analgesic
310	use and pain NRS scores, and using leave-one-out meta-analyses, did not show
311	material differences from the primary results in terms of treatment effect estimates or
312	heterogeneity (data not shown).

313

314 **DISCUSSION**

This study sought to determine the frequency of reporting concurrent analgesics use 315 at baseline and post-randomization among interventional pain RCTs included in a high-316 317 quality systematic review of interventional procedural treatments for pain. We also 318 conducted a meta-analysis to determine if accounting for concurrent analgesic use in 319 analyses of pain intensity using a novel composite pain intensity-analgesia outcome, the 320 QPAC_{1.5}, would produce a significantly larger treatment effect size than analyses of the 321 conventional pain NRS. We found that only half of the trials studied reported whether 322 concurrent analgesics were used at baseline and post-randomization, and only one trial 323 directly accounted for concurrent analgesic use post-randomization in the primary pain

intensity outcome.¹⁴ Our meta-analysis found that accounting for concurrent analgesic
use with the QPAC_{1.5} led to statistically significantly larger treatment effects on pain
intensity of -0.45 NRS points (95%CI -0.76 to -0.14) compared to analyses of pain
intensity using the conventional NRS.

Randomized controlled pain trials are very important for determining the 328 effectiveness of new interventional pain medicine treatments. Recent work suggests 329 330 that a seemingly minor secondary outcome reported in pain RCTs, concurrent analgesic use, can have a substantial impact on overall treatment effect estimates, sometimes 331 affecting whether a trial yields a statistically significant result for the primary pain 332 intensity endpoint.⁶ The current study highlights that only half of interventional pain trials 333 334 studied in a major systematic review reported concurrent analgesic use. Moreover, 335 when pain trials do assess and report concurrent analgesic use, they usually report it as the prevalence of any analgesic used and do not directly account for this use in their 336 337 primary outcomes. Assessing analgesic use as a binary outcome does not allow 338 investigators to account for analgesic use in the analyses of treatment effects on pain 339 intensity, but treats analgesic use as a distinct outcome, when in actuality both pain 340 intensity and analgesic use outcomes reflect different aspects of the same pain 341 construct (improvement in pain intensity). This can alter treatment effect estimates and 342 potentially fundamentally affect the main conclusions drawn from a pain RCT. A unique 343 finding from the current study is that accounting for concurrent analgesic use when analyzing pain intensity outcomes using the QPAC_{1.5} increased treatment effect 344 estimates on pain intensity by nearly 0.5 NRS points, indicating a larger beneficial effect 345 346 of the procedural treatments studied. One out of 5 trials in the meta-analysis shifted

from having non-significant to significant effects on pain intensity after applying the QPAC_{1.5}.¹⁶ This illustrates how accounting for analgesic use and pain intensity in the same composite outcome can potentially improve the power of pain RCTs and even affect the main conclusions drawn from certain trials. This finding is consistent with prior work,⁵ supporting the composite score's validity.

352 The current study's findings reinforce the need to uniformly report and account for analgesic use in interventional pain trials. The pre-specified subset of RCTs we selected 353 for the current meta-analysis was chosen specifically because they included treatment 354 vs. control contrasts where large treatment effects on pain intensity were expected. This 355 356 is the context in which larger between-group differences in analgesic would be 357 expected, resulting in larger estimates of the treatment effects on pain intensity when using the QPAC_{1.5}. It cannot be expected that the QPAC_{1.5} will always increase 358 359 treatment effect size estimated on pain intensity when applied to RCT data, however, 360 and in the context of an RCT of a treatment with no meaningful treatment effect on pain 361 intensity, the QPAC_{1.5} would not be expected to produce a net increase in treatment effect size. 362

One implication of this study is that a lack of accounting for concurrent analgesic use may increase the proportion of trials not finding statistically significant between-group differences in treatment effects and may decrease the size of the estimated treatment effects such that clinically relevant treatment effects are interpreted as not being clinically relevant.²⁰ This may carry forward into evidence synthesis and clinical practice guidelines, resulting in potentially effective pain treatments being discarded. This

possibility suggests that further studies of methods to account for concurrent analgesic
 use in pain RCTs should perhaps be a high priority for future research.

371 A strength of the current work is that it is the first comprehensive study to examine the frequency of reporting of concurrent analgesic use and the impact of analgesic use 372 on the overall treatment effects of interventional pain trials. Limitations include the fact 373 374 that we included clinical trials from only one systematic review of interventional pain trials from 2021, which focused primarily on emerging interventional treatments. These 375 findings therefore may not represent other trials of other pain treatments, nor the current 376 state of pain trials reported in the last 4 years. While responder outcomes were not 377 examined in this study, as the $QPAC_{1,5}$ is oriented towards analysis of mean outcomes 378 379 and the same responder outcomes were not reliably reported across studies (i.e., not permitting meta-analysis), the QPAC_{1.5} approach could be converted into a binary 380 responder outcome. Furthermore, heterogeneity was high in the meta-analyses we 381 382 conducted, but was consistently high with or without applying the QPAC_{1.5}. We used a 383 random-effects meta-analysis to account for this, yet despite the often lower power of 384 this meta-analytic approach, we still found statistically significant results. Nevertheless, 385 future studies are needed to evaluate the applicability of the current findings to trials of 386 other procedural and non-procedural pain treatments.

387

388 CONCLUSIONS

This study found that about half of non-surgical interventional pain RCTs from a major systematic review did not report on post-randomization concurrent analgesic use,

and that only one trial accounted for analgesic use directly in analyses of treatment
effects on pain intensity at the primary trial endpoint. When accounting for concurrent
analgesic use with the $QPAC_{1.5}$ in a meta-analysis, treatment effects on pain intensity
were nearly 0.5 NRS points larger compared to when concurrent analgesic use was
ignored. Future studies are needed to determine how pain trials should best account for
concurrent analgesic use in the analyses of pain intensity outcomes. Applying those
methods to pain RCTs may improve our ability to identify treatments with clinically
relevant effects.
ACKNOWLEDGEMENTS
We thank Coralynn Sack, MD, MPH for providing feedback on the final manuscript.
Funding source: We thank the UW CLEAR Center for partial study funding and
provision of methodologic guidance by the CLEAR Center Methodologic Core.

407 **REFERENCES**

- Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington (DC); 2011.
- Dzau V, Pizzo P. Relieving pain in America: insights from an Institute of Medicine
 committee.itle. *JAMA*. 2014;312:1507-1508.
- 412 3. Chou R, Deyo R, Friedly J, Al. E. *Noninvasive Treatments for Low Back Pain*.
 413 Rockville, MD; 2016.
- 414 4. Skelly A, Chou R, Dettori J, Al. E. *Noninvasive Nonpharmacological Treatment for* 415 *Chronic Pain: A Systematic Review Update.* Rockville (MD); 2020.
- Suri P, Heagerty PJ, Korpak A, et al. Improving Power and Accuracy in
 Randomized Controlled Trials of Pain Treatments by Accounting for Concurrent
 Analgesic Use. *J Pain*. 2023;24(2):332-344. doi:10.1016/j.jpain.2022.09.017
- Suri P, Heagerty P, Timmons A, Jensen M. Description and initial validation of a
 novel measure of pain intensity: the Numeric Rating Scale of Underlying Pain
 without concurrent Analgesic use. *Pain*. 2024;165(7):1482-1492.
- 422 7. Grøvle L, Hasvik E, Haugen AJ. Impact of rescue medication in placebo423 controlled trials of pharmacotherapy for neuropathic pain and low back pain. *Pain*.
 424 2022;163(3):E417-E425. doi:10.1097/j.pain.0000000002380
- 8. Chou R, Fu R, Dana T, Pappas M, Hart E, Mauer KM. Interventional Treatments for Acute and Chronic Pain: Systematic Review. 2021;(247).
 https://effectivehealthcare.ahrq.gov/products/interventional-treatmentspain/research.
- 9. Sridhar B, Staab C, Suri P. A Meta-Epidemiologic Study of Methods used to
 Account for Concurrent Treatments in Randomized Controlled Trials of Pain
 Interventions. Open Science Framework.
- 432 10. Estimation methods for estimands using the treatment policy strategy; a
 433 simulation study based on the PIONEER 1 TRIAL. *arXiv*. 2024.
- 434 11. Cohen SP, Bhaskar A, Bhatia A, et al. Consensus practice guidelines on
 435 interventions for lumbar facet joint pain from a multispecialty, international working
 436 group. *Reg Anesth Pain Med.* 2020;0:1-44. doi:10.1136/rapm-2019-101243
- 437 12. Oliveira C, Maher C, Ferreira M, et al. Epidural corticosteroid injections for
 438 lumbosacral radicular pain. *Cochrane Database Syst Rev.* 2020;(4).
- Peng B, Pang X, Wu Y, Zhao C, Song X. A randomized placebo-controlled trial of intradiscal methylene blue injection for the treatment of chronic discogenic low back pain. *Pain*. 2010;149(1):124-129.
- 14. Deer T, Pope J, Benyamin R, et al. Prospective, Multicenter, Randomized,

443 Double-Blinded, Partial Crossover Study to Assess the Safety and Efficacy of the
 444 Novel Neuromodulation System in the Treatment of Patients With Chronic Pain of
 445 Peripheral Nerve Origin. *Neuromodulation*. 2016;19(1):91-100.

- Blasco J, Martinez-Ferrer A, MacHo J, et al. Effect of vertebroplasty on pain relief,
 quality of life, and the incidence of new vertebral fractures: A 12-month
 randomized follow-up, controlled trial. *J Bone Miner Res.* 2012;27(5):1159-1166.
 doi:10.1002/jbmr.1564
- Chen D, An Z, Song S, Al. E. Percutaneous vertebroplasty compared with
 conservative treatment in patients with chronic painful osteoporotic spinal
 fractures. *J Clin Neurosci*. 2014;21(3):473-477.
- 453 17. Berenson J, Pflugmacher R, Jarzem P, Al. E. Balloon kyphoplasty versus non 454 surgical fracture management for treatment of painful vertebral body compression
 455 fractures in patients with cancer: a multicentre, randomised controlled trial. *Lancet* 456 *Oncol.* 2011;12(3):225-235.
- 457 18. Wardlaw D, Cummings S, Van Meirhaeghe J, Al. E. Efficacy and safety of balloon
 458 kyphoplasty compared with nonsurgical care for vertebral compression fracture
 459 (FREE): a randomised controlled trial. *Lancet.* 2009;373(9668):1016-1024.
- 460 19. Cohen S, Hurley R, Buckenmaier C, Al. E. Randomized placebo-controlled study
 461 evaluating lateral branch radiofrequency denervation for sacroiliac joint pain.
 462 Anesthesiology. 2008;109(2):279-288.
- Finnerup, NB Haroutounian S, Baron R, Dworkin R, et al. Neuropathic pain
 clinical trials: factors associated with decreases in estimated drug efficacy. *Pain*.
 2018;159(11):2339-2346.

466

467 **FIGURE LEGENDS**

468

469

- Figure 1. Forest plot of the difference in the treatment effect on the conventional pain
- intensity NRS (ignoring concurrent analgesic use) vs. the treatment effect on the
- 472 $QPAC_{1.5}$ (n=5 trials)

473

- Point estimates less than 0 indicate that the treatment effect on pain intensity using the
- 475 QPAC_{1.5} is, on average, larger than the treatment effect on pain intensity using the
- 476 conventional pain NRS. Whiskers show the bounds of the 95% confidence intervals.

Table 1. Characteristics of Analyzed Trials					
Author	Year	Intervention	Control (sham vs usual care)	Number randomized to intervention	Number randomized to control
Buchbinder	2009	Vertebroplasty	Sham	38	40
Blasco	2012	Vertebroplasty	Usual care	64	61
Yang	2016	Vertebroplasty	Usual care	66	69
Clark	2016	Vertebroplasty	Sham	61	59
Firanescu	2018	Vertebroplasty	Sham	91	89
Hansen	2019	Vertebroplasty	Sham	26	26
Kallmes	2009	Vertebroplasty	Sham	68	63
Chen	2014	Vertebroplasty	Usual care	46	50
Farrokhi	2011	Vertebroplasty	Usual care	40	42
Klazen	2010	Vertebroplasty	Usual care	93	95
Leali	2016	Vertebroplasty	Usual care	200	200
Rousing	2009	Vertebroplasty	Usual care	26	24
Voormolen	2007	Vertebroplasty	Usual care	18	16
Berenson	2011	Kyphoplasty	Usual care	70	64
Wardlaw	2009	Kyphoplasty	Usual care	149	151
Cady	2015	Sphenopalatine nerve block	Usual care	27	14
Serra	2012	Occipital nerve stimulation	Sham	16	16
Silberstein	2012	Occipital nerve stimulation	Sham	105	52
Saper	2011	Occipital nerve stimulation	Usual care	49	17
Cohen	2008	Cooled radiofrequency ablation	Sham	14	14
Patel	2012	Cooled radiofrequency ablation	Sham	34	17
McCormick	2019	Cooled radiofrequency ablation	Usual care	21	18
Kroll	2008	Pulsed radiofrequency ablation	Continuous RFA	13	13
Moussa	2020	Pulsed radiofrequency ablation	Sham and continuous RFA	100	50
Tekin	2007	Pulsed radiofrequency ablation	Sham and continuous RFA	20	40
Wosornu	2016	Intradiscal PRP Injection	Sham	36	22
Amirdelfan	2020	Intradiscal Stem Cell Injection	Sham	30	20
Kallewaard	2019	Intradiscal Methylene Blue Injection	Sham	40	41
Peng	2010	Intradiscal Methylene Blue Injection	Sham	36	36
Haseeb	2019	Intradiscal Ozone Injection	Sham	80	20
Nilachandra	2016	Intradiscal Ozone Injection	Usual care	40	40
Gallucci	2007	Intradiscal Ozone Injection	Usual care	82	77
Childers	2002	Piriformis Injection	Sham	5	5
Fishman	2002	Piriformis Injection	Sham	63	24
Fishman	2017	Piriformis Injection	Sham	26	28
Misirlioglu	2015	Piriformis Injection	Sham	25	22
Deer	2016	Peripheral nerve stimulation	Sham	45	49

477

Analgesic use Characteristics n (%)				
Reported analgesic use at baseline (any method)	17 (46%)			
Method used to report concurrent analgesia*				
Average dose of medication	4 (11%)			
Prevalence of any opioid use	11 (30%)			
Prevalence of non-opioid use	7 (19%)			
Prevalence of individual medication use	1 (3%)			
Prevalence of any analgesic use	7 (19%)			
Other method	1 (3%)			

*Some studies reported more than one method

478

Table 3. Reporting on Concurrent Analgesic Use Post-Randomization Among Included RCTs (n=37)

Analgesic use Characteristics	n (%)
Reported analgesic use post-randomization (any method)	20 (54%)
Method used to report concurrent analgesia	
Average dose of medication	1 (3%)
Prevalence of any opioid use	4 (11%)
Prevalence of non-opioid use	3 (8%)
Prevalence of individual medication use	1 (3%)
Prevalence of any analgesic use	11 (30%)
Other method	4 (11%)

479

480

481

